scholarly journals Targeting breast cancer cells with a CuInS2/ZnS quantum dot-labeled Ki-67 bioprobe

2017 ◽  
Author(s):  
Guang Sun ◽  
Wanying Xing ◽  
Ren Xing ◽  
Liu Cong ◽  
Sun Tong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantum Dot ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Ki 67

scholarly journals Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells

2021 ◽  
Vol 14 (3) ◽  
pp. 254
Author(s):  
Afnan H. El-Gowily ◽  
Samah A. Loutfy ◽  
Ehab M. M. Ali ◽  
Tarek M. Mohamed ◽  
Mohammed A. Mansour
Keyword(s):  
Breast Cancer ◽  
Combination Therapy ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Mtor Pathway ◽  
Tumor Growth Inhibition ◽  
Autophagic Flux ◽  
Ki 67 ◽  
Mcf 7

Cancer is a complex devastating disease with enormous treatment challenges, including chemo- and radiotherapeutic resistance. Combination therapy demonstrated a promising strategy to target hard-to-treat cancers and sensitize cancer cells to conventional anti-cancer drugs such as doxorubicin. This study aimed to establish molecular profiling and therapeutic efficacy assessment of chloroquine and/or tioconazole (TIC) combination with doxorubicin (DOX) as anew combination model in MCF-7 breast cancer. The drugs are tested against apoptotic/autophagic pathways and related redox status. Molecular docking revealed that chloroquine (CQ) and TIC could be potential PI3K and ATG4B pathway inhibitors. Combination therapy significantly inhibited cancer cell viability, PI3K/AkT/mTOR pathway, and tumor-supporting autophagic flux, however, induced apoptotic pathways and altered nuclear genotoxic feature. Our data revealed that the combination cocktail therapy markedly inhibited tumor proliferation marker (KI-67) and cell growth, along with the accumulation of autophagosomes and elevation of LC3-II and p62 levels indicated autophagic flux blockage and increased apoptosis. Additionally, CQ and/or TIC combination therapy with DOX exerts its activity on the redox balance of cancer cells mediated ROS-dependent apoptosis induction achieved by GPX3 suppression. Besides, Autophagy inhibition causes moderately upregulation in ATGs 5,7 redundant proteins strengthened combinations induced apoptosis, whereas inhibition of PI3K/AKT/mTOR pathway with Beclin-1 upregulation leading to cytodestructive autophagy with overcome drug resistance effectively in curing cancer. Notably, the tumor growth inhibition and various antioxidant effects were observed in vivo. These results suggest CQ and/or TIC combination with DOX could act as effective cocktail therapy targeting autophagy and PI3K/AKT/mTOR pathways in MCF-7 breast cancer cells and hence, sensitizes cancer cells to doxorubicin treatment and combat its toxicity.

Antisense Ki-67 cDNA Transfection Reverses the Tumorigenicity and Induces Apoptosis in Human Breast Cancer Cells

2008 ◽  
Vol 26 (8) ◽  
pp. 830-835 ◽  
Author(s):  
Rui Wang ◽  
Danfeng Luo ◽  
Xiangyi Ma ◽  
Wanhua Yang ◽  
Rui Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Ki 67

scholarly journals PEAK1 promotes invasion and metastasis and confers drug resistance in breast cancer

2021 ◽  
Author(s):  
Xingang Wang ◽  
Yan Zheng ◽  
Yu Wang
Keyword(s):  
Breast Cancer ◽  
Cell Growth ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Chemotherapy Resistance ◽  
Ki 67 ◽  
Cancer Tissues

AbstractPseudopodium-enriched atypical kinase 1 (PEAK1) has been reported to be upregulated in human malignancies and is correlated with a poor prognosis. Enhanced PEAK1 expression facilitates tumor cell survival, invasion, metastasis and chemoresistance. However, the role of PEAK1 in breast cancer is unclear. We investigated PEAK1 expression in breast cancer and analyzed the relationship with clinicopathological status and chemotherapy resistance. We also investigated the role of PEAK1 in breast cancer cells in vitro and in vivo. Immunohistochemistry for PEAK1 was performed in 112 surgically resected breast cancer tissues. The association between clinicopathological status, chemotherapy resistance and PEAK1 expression was determined. The effect of PEAK1 overexpression or downregulation on proliferation, colony formation, invasion, migration, metastasis and doxorubicin sensitivity in MCF-7 cells in vitro and in vivo was studied. PEAK1 was overexpressed in breast cancer tissues. High PEAK1 expression was correlated with tumor size, high tumor grade, tumor stage, lymph node metastasis, recurrence, Ki-67 expression, Her-2 expression and chemotherapy resistance. Inhibiting PEAK1 decreased cell growth, invasion, metastasis and reversed chemoresistance to doxorubicin in breast cancer cells both in vitro and in vivo. High PEAK1 expression was associated with the invasion, metastasis and chemoresistance of breast cancers. Furthermore, targeting PEAK1 inhibited cell growth and metastasis and reversed chemoresistance in breast cancer cells. Targeting PEAK1 could be an effective treatment strategy for breast cancer.

scholarly journals Overexpression of LncRNA BM466146 Predicts Better Prognosis of Breast Cancer

2021 ◽  
Vol 10 ◽  
Author(s):  
Yunxiang Zhang ◽  
Xiaotong Dong ◽  
Yang Wang ◽  
Liquan Wang ◽  
Guiyan Han ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Analysis ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Target Genes ◽  
Ki 67 ◽  
Cd8 Cells ◽  
Kaplan Meier ◽  
Cancer Tissues ◽  
Breast Tissues

This study analyzes the expression and clinical significance of long non-coding RNA (lncRNA) BM466146 in breast cancer, and explores the role of BM466146 in immune regulation. The expression of BM466146 in 89 cases of breast cancer and their corresponding non-cancerous breast tissues was detected by quantitative real-time polymerase chain reaction (qRT-PCR). Kaplan-Meier survival analysis was applied to evaluate patient survival. EDU and CCK-8 experiments on breast cancer cells were performed to verify the function of BM466146 in vitro. The target genes of BM466146 were screened by informatics analysis to predict associated miRNAs and their corresponding mRNAs, immune genes associated with lncRNAs and chemokines associated with CD8. Immunohistochemistry was used to detect the expression of CD8, Ki-67, and CXCL-13 in the 89 breast cancer tissues. It was found that the expression of lncRNA BM466146 in breast cancer tissues was significantly lower than that in normal breast tissues (P < 0.001). In breast cancer, tissues that overexpressed BM466146 exhibited a lower Ki-67 index compared with that of low BM466146 expression (P = 0.048). Kaplan-Meier survival analysis showed that breast cancer patients with overexpression of BM466146 had longer overall survival. EDU and CCK8 experiments showed that overexpression of BM466146 inhibited the proliferation of breast cancer cells. The hsa-miR-224-3p is associated with BM466146, and its target gene might be CXCL-13. The positive CD8 cells in the BM466146 overexpression group was higher than that in the low BM466146 expression group (P=0.027), and the positive CD8 cells in the CXCL-13 positive group was higher (P=0.023) than that of the negative group. Our results indicate that the lncRNA BM466146 has the function of tumor suppressor gene. Overexpression of BM466146 is associated with better prognosis. BM466146 could regulate CXCL-13 by adsorbing hsa-miR-224-3p and inducing CD8+ T cells to accumulate in the tumor area which regulate immune response. Therefore, BM466146 could be a prognostic biomarker and a molecular immune target of breast cancer.

MIB-1 (Ki-67) Immunostaining of Breast Cancer Cells in Cytologic Smears

1997 ◽  
Vol 41 (2) ◽  
pp. 229-237 ◽  
Author(s):  
Peter Dalquen ◽  
Betty Baschiera ◽  
Rosemarie Chaffard ◽  
Holger Dieterich ◽  
Georg E. Feichter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Ki 67 ◽  
Mib 1

Determining the Efficiency of Single Molecule Quantum Dot Labeling of HER2 in Breast Cancer Cells

Nano Letters ◽  
2020 ◽  
Vol 20 (11) ◽  
pp. 7948-7955 ◽  
Author(s):  
Diana B. Peckys ◽  
Cedric Quint ◽  
Niels de Jonge
Keyword(s):  
Breast Cancer ◽  
Quantum Dot ◽  
Cancer Cells ◽  
Single Molecule ◽  
Breast Cancer Cells

Quantum dot-induced epigenetic and genotoxic changes in human breast cancer cells

2007 ◽  
Vol 86 (3) ◽  
pp. 291-302 ◽  
Author(s):  
Angela O. Choi ◽  
Shelley E. Brown ◽  
Moshe Szyf ◽  
Dusica Maysinger
Keyword(s):  
Breast Cancer ◽  
Quantum Dot ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast

scholarly journals Hsa_circ_0029693 (circ-LATS2) promotes cell proliferation and regulates WNT5A via miR-4686 in breast cancer cells.

2020 ◽  
Author(s):  
Jiashu Hu ◽  
Kaiyao Hua ◽  
Changle Ji ◽  
Xuehui Wang ◽  
Hongming Song ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Proliferation ◽  
Western Blot ◽  
Cancer Cells ◽  
Immunohistochemical Staining ◽  
Breast Cancer Cells ◽  
Hippo Pathway ◽  
Luciferase Reporter ◽  
Ki 67 ◽  
Reporter Assays

Abstract Background: Breast cancer (BC) is the most malignant form of tumor in women, which threatens females’ health. Circular RNAs (circRNAs), a class of non-coding RNAs, can act as a disease biomarker and endogenous “sponge” molecules for microRNAs (miRNAs). circRNAs may also influence the expression of their parent gene. LATS2 is a vital suppressor gene in Hippo pathway, which is a signaling cascade composed of a group of conserved kinases. The Hippo pathway plays an important role in almost all cancer types. Methods: Colony formation assays, MTT assays, wound healing assays, xenografts mice experiment, qRT-PCR, western blot assays, immunohistochemical staining assays, dual-luciferase reporter assays and Fluorescence in situ hybridization. Student’s t-test was used to analyse the results.Results: We discovered that circular RNA hsa_circ_0029693 (circ-LATS2), an exonic circRNA, are highly expressed in breast cancer cells. Furthermore, in BC patients’ samples, higher expression of circ-LATS2 was significantly related to higher percentage of Ki-67 expression; however the expression of circ-LATS2 was higher in HER2 negative BC patients compared to HER2 positive ones. We investigated the potential function and mechanism of circ-LATS2 action in BC. The results suggested that circ-LATS2 promoted cell proliferation, growth and migration. Through western blot and immunohistochemical staining assays, we found that circ-LATS2 could influence LATS2 expression. We also discovered that there was an inverse expression relationship between miR-4686 and circ-LATS2, suggesting that circ-LATS2 might act as an endogenous “sponge” for miR-4686. Using dual-luciferase reporter assays, we confirmed that circ-LATS2 can bind miR-4686. Increased miR-4686 expression caused a reduction in the protein levels of WNT5A, which is a putative target of miR-4686. We confirm this using dual-luciferase reporter assays that revealed that miR-4686 targets WNT5A by binding its 3’-untranslated region (3’UTR). Conclusions: Our results showed that circ-LATS2 expression in BC patients’ samples were significantly related to Ki-67 expression. In addition, circ-LATS2 acted as a promoter of proliferation and growth of breast cancer cells. These indicated that circ-LATS2 is a proliferative factor, similar to Ki-67; it also acts as a co-biomarker with Ki-67 in clinical treatment.

Sign in / Sign up

Export Citation Format

Share Document